The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis

Infection and Immunity

Volumn 68, Issue 3, 2000, Pages 1312-1318

  Reichmann, Gaby ^a,c   Walker, William ^b   Villegas, Eric N ^a   Craig, Linden ^a   Cai, Guifang ^a   Alexander, James ^b   Hunter, Christopher A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; ENCEPHALITIS; INFECTION RESISTANCE; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TOXOPLASMA; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; ENCEPHALITIS; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED CBA; NITRIC OXIDE; TH1 CELLS; TOXOPLASMOSIS, CEREBRAL;

EID: 0033982191     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.3.1312-1318.2000     Document Type: Article

References (48)

1. Abrams, J. S., M. G. Roncarolo, H. Yssel, G. J. Andersson, and J. E. Silver. 1992. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127:5-24.
2. 2 secretion by microglia during antigen presentation to Th1 cells. J. Immunol. 162:1384-1391.
3. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94:599-603.
4. Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, and C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4:283-289.
5. Campos-Neto, A., P. Ovendale, T. Bement, T. A. Koppi, W. C. Fanslow, M. A. Rossi, and M. R. Alderson. 1998. CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J. Immunol. 160:2037-2041.
6. Candolfi, E., C. A. Hunter, and J. S. Remington. 1995. Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis. Infect. Immun. 63:751-756.
7. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
8. Cosyns, M., S. Tsirkin, M. Jones, R. Flavell, H. Kikutani, and A. R. Hayward. 1998. Requirement for CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect. Immun. 66:603-607.
9. Deckert-Schluter, M., H. Bluethmann, A. Rang, H. Hof, and D. Schluter. 1998. Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis. J. Immunol. 169:3427-3436.
10. Denkers, E. Y., and R. T. Gazzinelli. 1998 Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:569-588.
11. Gazzinelli, R. T., S. Bala, R. Stevens, M. Baseler, L. Wahl, J. Kovacs, and A. Sher. 1995. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J. Immunol. 155:1565-1574.
12. Gazzinelli, R. T., I. Eltoum, T. A. Wynn, and A. Sher. 1993. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-α and correlates with the downregulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J. Immunol. 151:3672-3681.
13. Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher. 1994. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153:2533-2543.
14. Gerritse, K., J. D. Laman, R. J. Noelle, A. Aruffo, J. A. Ledbetter, W. J. A. Boersma, and E. Claassen. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 93:2499-2504.
15. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135.
16. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, and R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273:1864-1867.
17. Grewal, I. S., J. Xu, and R. A. Flavell. 1996. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378:617-620.
18. Howard, L. M., A. J. Miga, C. L. Vanderlugt, M. C. Dal Canto, J. D. Laman, R. J. Noelle, and S. D. Miller. 1999. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Investig. 103:281-290.
19. Hunter, C. A., L. Ellis-Neyer, K. Gabriel, M. Kennedy, P. Linsley, and J. S. Remington. 1997. The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J. Immunol. 158:2285-2293.
20. Israelski, D. M., J. S. Chmiel, L. Poggensee, J. P. Phair, and J. S. Remington. 1993. Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J. Acquir. Immune Defic. Syndr. 6:414-418.
21. Israelski, D. M., and J. S. Remington. 1993. Toxoplasmosis in patients with cancer. Clin. Infect. Dis. 17(Suppl.):S423-S435.
22. Kamanaka, M., P. Yu, T. Yasui, K. Yoshida, T. Kawabe, T. Horii, T. Kishimoto, and H. Kikutani. 1996. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 4:275-281.
23. Kennedy, M. K., K. S. Picha, W. C. Fanslow, K. H. Grabstein, M. R. Alderson, K. N. Clifford, W. A. Chin, and M. M. Mohler. 1996. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26:370-378.
24. Leiva, L. E., J. Junprasert, D. Hollenbaugh, and R. U. Sorensen. 1998. Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. J. Clin. Immunol. 18:283-290.
25. Levy, J., T. Espanol-Boren, C. Thomas, A. Fischer, P. Tovo, P. Bordigoni, I. Resnick, A. Fasth, M. Baer, L. Gomez, E. A. Sanders, M. D. Tabone, D. Plantaz, A. Etzioni, V. Monafo, M. Abinun, L. Hammarstrom, T. Abrahamsen, A. Jones, A. Finn, T. Klemola, E. DeVries, O. Sanal, M. C. Peitsch, and L. D. Notarangelo. 1997. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131:47-54.
26. Notarangelo, L. D., M. Duse, and A. G. Ugazio. 1992. Immunodeficiency with hyper-IgM (HIM). Immunodefic. Rev. 3:101-121.
27. Peng, X., A. Kasran, P. A. Warmerdam, M. de Boer, and J. L. Ceuppens. 1996. Accessory signalling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-γ production. Eur. J. Immunol. 26:1621-1627.
28. Reichmann, G., E. N. Villegas, L. Craig, R. Peach, and C. A. Hunter. 1999. The CD28/B7 interaction is not required for resistance to Toxoplasma gondii in the brain but contributes to the development of immunopathology. J. Immunol. 163:3354-3362.
29. Reise Sousa, B. C., S. Hieny, T. Scharton-Kersten, D. Jankovic, H. Charset, R. N. Germain, and A. Sher. 1997. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186:1819-1829.
30. Saito, K., J. Sakurai, J. Ohata, T. Kohsaka, H. Hashimoto, K. Okumura, R. Abe, and M. Azuma. 1998. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J. Immunol. 160:4225-4231.
31. Sander, B., I. Hoiden, U. Andersson, E. Moller, and J. S. Abrams. 1993. Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. J. Immunol. Methods 166:201-214.
32. Scharton-Kersten, T. M., G. Yap, J. Magram, and A. Sher. 1997. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 185:1261-1273.
33. Sedgwick, J. D., S. Schwender, H. Imrich, R. Dorries, G. W. Butcher, and V. ter Meulen. 1991. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. USA 88:7438-7442.
34. Sharma, S. D., J. Mullenax, F. G. Araujo, A. A. Erlich, and J. S. Remington. 1983. Western blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J. Immunol. 131:977-983.
35. Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzio, M. Gately, and G. Delespesse. 1995. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125-1128.
36. Slavin, M. A., J. D. Meyers, J. S. Remington, and R. C. Hackman. 1994. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant. 13:549-557.
37. Soong, L., J.-C. Xu, I. S. Grewa, P. Kima, J. Sun, B. J. Longley, N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263-273.
38. Stout, R. D., J. Suttles, J. Xu, I. S. Grewal, and R. A. Flavell. 1996. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156:8-11.
39. Stuber, E., W. Strober, and M. Neurath. 1996. Blocking the CD40-CD40L interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693-698.
40. Subauste, C. S., M. Wessendarp, R. U. Sorensen, and L. E. Leiva. 1999. CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. J. Immunol. 162:6690-6700.
41. Suzuki, Y., M. A. Orelana, R. D. Schreiber, and J. S. Remington. 1988. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science 240:516-518.
42. Tsuge, I., H. Matsuoka, A. Nakagawa, Y. Kamachi, K. Aso, T. Negoro, M. Ito, S. Torii, and K. Watanabe. 1998. Necrotizing toxoplasmic encephalitis in a child with the X-linked hyper-IgM syndrome. Eur. J. Pediatr. 157:735-737.
43. van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 378:620-623.
44. Wiley, J. A., and A. G. Harmsen. 1995. CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J. Immunol. 155:3525-3529.
45. Yang, Y., and J. M. Wilson. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signalling through CD40. Science 273:1862-1864.
46. Yap, G. S., T. Scharton-Kersten, H. Charest, and A. Sher. 1998. Decreased resistance of TNF receptor p55-and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J. Immunol. 160:1340-1345.
47. Yap, G. S., and A. Sher. 1999. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-γ-and tumor necrosis factor (TNF)-α-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J. Exp. Med. 189:1083-1092.
48. Zhou, P., and R. A. Seder. 1998. CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with Histoplasma capsulatum. J. Exp. Med. 187:1315-1324.